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Tumor-Associated Macrophages (TAMs) are abundantly present in the stroma of solid tumors and modulate several important
biological processes, such as neoangiogenesis, cancer cell proliferation and invasion, and suppression of adaptive immune
responses. Myeloid C-type lectin receptors (CLRs) constitute a large family of transmembrane carbohydrate-binding receptors
that recognize pathogens as well as endogenous glycoproteins. Several lines of evidence demonstrate that some CLRs can inhibit
the immune response. In this study we investigated TAM-associated molecules potentially involved in their immune suppressive
activity. We found that TAMs isolated from human ovarian carcinoma samples predominantly express the CLRs Dectin-1, MDL-1,
MGL, DCIR, and most abundantly the Mannose Receptor (MR). Components of carcinomatous ascites and purified tumoral
mucins (CA125 and TAG-72) bound theMR and induced its internalization.MR engagement by tumoralmucins and by an agonist
anti-MR antibody modulated cytokine production by TAM toward an immune-suppressive profile: increase of IL-10, absence of
IL-12, and decrease of the Th1-attracting chemokine CCL3. This study highlights that tumoral mucin-mediated ligation of the
MR on infiltrating TAM may contribute to their immune suppressive phenotype.
1. Introduction
Among tumor-infiltrating leukocytes, Tumor-Associated
Macrophages (TAMs) constitute a major subset [1–3]. While
the presence of T lymphocytes in tumor stroma is usually
correlated with more favourable prognosis of cancer patients
[4, 5], in most studies the density of TAM is associated with
rapid tumor progression [6–9]. TAMs are poorly cytotoxic
against neoplastic cells and may actually favour tumor cell
survival and proliferation by actively producing growth
factors for cancer and endothelial cells. They are also a
major source of proteolytic enzymes that degrade the extra-
cellular matrix thus favouring the invasion of neoplastic cells
[9, 10]. Further, TAM contributes to the evasion of tumors
from immune control by producing immune-suppressive
cytokines such as IL-10 and TGFβ [2, 9].
Our group proposed that TAMs are M2-like polar-
ized macrophages [11]. Along a conventional definition,
macrophages activated in the presence of inflammatory
mediators (e.g., LPS) and Th1 cytokines (e.g., IFNγ) are
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defined as M1 or classically activated macrophages. These
eﬀectors have high cytotoxic functions, produce immune-
stimulatory cytokines, and are important cells for the defense
against intracellular pathogens and transformed cells [11–
13]. On the other hand M2 macrophages, or alternatively
activated macrophages, diﬀerentiate in microenvironments
rich in anti-inflammatory mediators or Th2 cytokines (e.g.,
IL-10, IL-4, IL-13); they have high scavenging activity, pro-
duce several growth factors, activating the process of tissue
regeneration, and suppress adaptive immune responses [2,
12, 14, 15]. While these activities are of extreme importance
during wound healing to return to the homeostatic state, in
the context of a growing tumor they are deleterious to the
host. Indeed several studies have found a strong correlation
between high numbers of TAM, number of vessels, and lower
disease-free survival [9, 10, 16–18].
In this study we investigated TAM-related mechanisms
of immune escape and considered C-type lectin receptors
(CLRs) as interesting candidates. CLRs are a large family
of structurally related transmembrane receptors which, by
virtue of their carbohydrate-recognition domains, bind high
aﬃnity sugar moieties present on the surface of pathogens
as well as of endogenous glycoproteins [19, 20]. Together
with the Toll-like receptor (TLR) family, CLRs expressed on
myeloid cells of the innate immunity constitute the major
system to sense the outer world [21–23]. Myeloid CLRs are
subdivided into two major families: the first including the
mannose receptor (MR, DEC206), ENDO180, DEC205, and
PLA2 receptor, and the second including DC-SIGN, Dectin-
1, Langerin, DCIR, MGL, and BDAC2 [24, 25].
Although the majority of studies have investigated
the role of CLRs in the recognition, internalization, and
clearance of pathogens through activation of innate immu-
nity, other studies have clearly demonstrated that at least
some receptors elicit anti-inflammatory/immune-suppres-
sive responses, raising the hypothesis that pathogens may
exploit CLR binding and internalization ability to overcome
innate immunity and survive within the host [22, 24, 25].
For instance, M. tuberculosis binds DC-SIGN and the MR
and inhibits the production of IL-12 [26–28]. We previously
reported in mono-DC that cross-linking of the MR with
an agonist antibody increased IL-10 production leading
to inhibition of IL-12 and defective Th1 diﬀerentiation
[27]. Activation of BDAC2, expressed by plasmacytoid DC,
as well as DCIR, downregulates the production of IFNα
[29, 30]. DCIR also interferes with GM-CSF signalling
[31]. The receptor MGL recognizes the isoform CD45RB
expressed by eﬀector memory T cells and negatively influ-
ences T cell receptor signalling [32]. Thus, several lines
of evidence point to a role of at least some CLRs in
the restriction of inflammatory reactions and in homeo-
stasis preservation [24, 25].
Of interest, CLRs recognize glycans expressed also on
endogenous ligands. For instance, the carbohydrate sialyl
LewisX -type expressed on lymphatic endothelium is recog-
nized by the MR and DC-SIGN [24, 33]. The latter also
binds vascular adhesion molecules [23]. The MR recog-
nizes selected hormones (thyroglobulin, luteotropin),matrix
molecules (chondroitin sulphate proteoglycans, collagen),
and enzymes (myeloperoxidase, lysosomal hydrolases) [20].
DC-SIGN,MGL, and MR bind epithelial mucins [24, 27, 34–
36]. The physiological significance of the recognition of
endogenous ligands by CLR is not fully characterized.
Previous studies on CLRs have been mainly performed
with in vitro generated macrophages and DC or with in vivo
mouse models of diseases. The aim of this study is to inves-
tigate the expression of CLRs in TAM. Here we show that
TAM isolated from human ovarian carcinoma samples pre-
dominantly expressed Dectin-1, MDL-1, MGL, DCIR, and
most abundantly the MR. Experiments demonstrated that
the MR recognizes ligands present in carcinomatous ascites
and tumoral mucins such as CA125 and tumor-associated
glycoprotein- (TAG-) 72. Upon mucin-engagement of the
MR, TAMs secrete higher levels of IL-10 and lower levels
of the T cell attracting chemokine CCL3. Thus, tumoral
mucin-mediated activation of the MR on TAM triggers an
immune-suppressive response which likely contributes to
tumor immune evasion.
2. Materials and Methods
2.1. Isolation of Human Tumor-Associated Macrophages
(TAMs). Having obtained an informed consent, we col-
lected carcinomatous ascites and/or tumor samples from
27 patients with histologically confirmed ovarian tumors.
TAMs were isolated from ascites by density Ficoll, and Percoll
gradients (Lonza, Italy) as described in [37]; TAMs from
solid tumors were isolated by enzymatic digestion and Ficoll
gradient [38] and were further purified by plastic adherence
(RPM1 1640 w/o FBS, 1h, 37◦C); adherent cells were usually
80–90% CD68+ macrophages as assessed by flow cytometry.
Human in vitro diﬀerentiated macrophages were ob-
tained by culture of monocytes with M-CSF (20 ng/mL)
[37] for 6 days [37]. Myeloid DCs were diﬀerentiated from
monocytes with GM-CSF (50 ng/mL) and IL-4 (20 ng/mL)
for 6 days [27].
2.2. Transcriptional Profile Analysis. TAMs from 7 diﬀerent
patients (5 from carcinomatous ascites and 2 from solid
tumors) were used for the transcriptional profiling exper-
iments. TAMs were either immediately processed or after
18-h stimulation with LPS (100 ng/mL) (Sigma, Italy) or IL-
10 (20 ng/mL) (Peprotech,Italy) (for 4 TAM preparations).
Macrophages from the peritoneal free-fluid of nontumoral
patients (ovarian cysts) were collected during surgery from
12 diﬀerent patients, centrifuged over Ficoll and immediately
processed for RNA (purity >90%). Total RNA was extracted
from 5×106 cells using Trizol (Invitrogen Life Technologies),
retrotranscribed and prepared for GeneChip hybridization as
previously described [38]. Each TAM preparation was inde-
pendently tested. Macrophages from nontumoral patients
were pooled to reach the minimum necessary amount for
1 GeneChip. Fragmented cRNA was hybridized to HG-
U133 Plus 2.0 GeneChips (Aﬀymetrix) and then washed and
scanned according to manufacturer’s guidelines. Expression
measures were computed using Robust Multiarray Average
(RMA). Statistical diﬀerences were assessed by a moderated
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t-test analysis performed using a Limma bioconductor
package, and resulting P-values were adjusted using the
Benjamini and Hochberg step-up method for controlling the
False Discovery Rate (FDR). Genes were defined as regulated
when characterized by a fold of induction≥2 and an FDR P-
value≤.05. Computations were conducted using the R statis-
tics programming environment (http://www.r-project.org/).
2.3. Phenotype Analysis. Tumor macrophages were analysed
by flow cytometry on FACS Canto (BD Bioscience, Milan,
Italy). Cells were first incubated with PBS 1%HS (30minutes
4◦C) to block FcγR, washed and resuspended in FACS buﬀer
(PBS 0.5% BSA, 0.05% NaN3). PE-mouse antihuman CD14
(clone M5E2) was purchased from (BD Pharmingen, Italy).
Three of mouse anti-human MR/CD206 were used with
identical results. Clone 19.2 was from BD Pharmingen; clone
PAM-1 was previously characterized [27]; clone WE458 was
in-house generated and selected for reactivity against MR-
transfected CHO cells.
2.4. Endocytosis Assay. Mannose receptor–mediated endocy-
tosis was measured as the cellular uptake of FITC-dextran
and quantified by flow cytometry. Approximately 2 × 105
cells per sample were incubated in media containing FITC-
dextran (1mg/mL) (molecular weight 40,000; Sigma) over
a period of 60min. After incubation, cells were washed
twice with phosphate-buﬀered saline (PBS) to remove excess
dextran and fixed in cold 1% formalin. Endocytosis was
expressed as fluorescence intensity, calculated as mean fluo-
rescence intensity of positive cells at 37◦C-mean fluorescence
intensity of positive cells at 4◦C.
2.5. Immunohistochemistry. Human surgical samples of
ovarian tumors were immediately frozen in OCT after
surgical collection. Sections were stained with anti-CD206
mAbs, followed by a goat antimouse secondary antibody
(EnVision horseradish peroxidase rabbit/mouse, DakoCy-
tomation). After a diaminobenzidine reaction (Liquid DAB
+ Substrate Chromogen System, Dako Cytomation), sections
were counterstained with hematoxylin (Mayer, DIAPATH).
2.6. Elisa. Cytokines were measured in supernatants of TAM,
macrophages, and Dendritic Cells (DCs) by commercially
available ELISA kits (IL-10, IL-12, CCL3) according to
manufacture’s instructions (R&D Systems, Space Import,
Milan, Italy). Cells were pretreated (10 min. room tem-
perature) with anti-CD206 (clone WE458, 2 ug/mL), or
tumoral mucins (Sigma) TAG-72 (200UI/mL) or CA125
(200UI/mL), prior to stimulation with LPS (1 ug/mL,
24 hours). TAG-72 and CA125 contained less than 0.125
endotoxin unit/mL as checked by Limulus amebocyte lysate
assay (BioWhittaker, Walkersville, MD).
2.7. Statistical Analysis. Prism software (GraphPad) and
Microsoft Excel were used for all statistical analyses. Student’s
t tests were used to determine statistically significant diﬀer-
ences between experimental groups. P < .05 was considered
to be statistically significant.
Table 1: Aﬀymetrix Gene Expression analysis of selected C-type
lectin receptors in human Tumor-AssociatedMacrophages (TAMs).
Gene symbol/
other names
Intensity◦
Modulation§
LPS/IFNγ
Modulation§
IL-10
MRC1/CD206
CLEC13D
562 ± 76 0,1∗ 1,5∗
Dectin-1
CLEC7A
482 ± 63 0,3∗ 1,4∗
MDL-1
CLEC5A
468 ± 94 0,3∗ 0,7
DCIR CLEC4A 359 ± 37 0,7 1,1
MGL-1/CD301
CLEC10A
258 ± 85 0,9 1,1
DCL-1/CD302
CLEC13A
160 ± 42 0.9 1
ENDO-
180/CD280
CLEC13E
111 ± 72 0,8 1
DEC-
205/CD205
CLEC13B
77 ± 42 2,9∗ 0,7
DC-
SIGN/CD209
CLEC4L
40 ± 13 0,8 0,9
Langerin/
CD207
CLEC4K
42 ± 11 0,9 0,9
PLA2R
CLEC13C
25 ± 6 1 1
◦Normalized intensity, §Fold over untreated TAM. Results are expressed as
median values ± SE of 7 diﬀerent TAM preparations and are presented as
normalized intensity signals: modulation of CLR genes after TAM treatment
with LPS/IFNγor IL-10 for 18 hrs. Results are presented as fold over
untreated TAM, ∗P < .05 versus untreated. Experiment of CLR modulation
by cytokines was performed in 4 TAM preparations.
3. Results
3.1. C-Type Lectin Receptor Gene Expression in Human TAM.
To study the expression of CLRs in TAM we interrogated our
Aﬀymetrix database performed with 7 diﬀerent populations
of purified TAM isolated from human ovarian carcinoma (5
from carcinomatous ascites and 2 from solid tumors). CLR
gene expression levels from TAM of solid tumors or from
ascitic fluids were similar and were considered together. The
most expressed CLR genes were themannose receptor (Mrc1,
CD206),Dectin1, DCIR MDL-1, andMGL-1 (Table 1). Other
CLR genes were expressed at very low level (e.g., DEC205,
DC-SIGN, PLA2R).
Modulation of CLR expression by LPS/IFNγ or IL-10 was
performed in 4 TAM samples. Exposure of TAM to LPS/IFNγ
induced a diﬀerent gene modulation with a prominent
increase of DEC205 (2.9-fold) and strong decrease of Mrc1
(0.1) and of MDL-1 (0.3). In contrast, pretreatment with
IL-10 upregulated Mrc1 by 1.5-fold (Table 1). It was of
interest to compare the gene expression analysis of TAM
with normal tissue macrophages. We had the opportunity
to test peritoneal free-fluid macrophages collected from
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Figure 1: Schematic representation of the relative expression of the eleven CLRs shown in Table 1, in tumoral macrophages (TAM) from
ovarian tumor samples and in nontumoral macrophages isolated from the peritoneal free-fluid of patients with benign diseases (ovarian
cysts).
nontumoral patients. As the amount of free-fluid and
the cellular content is usually very small, we pooled the
samples from 12 diﬀerent subjects who underwent surgery
for nonneoplastic diseases (ovarian cysts) and analyzed
with the same GeneChips (Aﬀymetrix) used with TAM.
Figure 1 shows that the relative expression of the eleven
CLRs analyzed was similar between TAM and normal tissue
macrophages, though some diﬀerences were noted: Mrc1,
MDL-1, and MGL-1 were higher in TAM, while Dectin1 and
DCIR and DCL-1 were higher in normal macrophages.
On the basis of these findings we further investigated the
mannose receptor (MR) in human TAM.
3.2. Phenotype and Functional Activity of the MR in Human
TAM. To check for protein expression, 12 diﬀerent prepa-
rations of human TAM were purified from the ascitic fluid
of patients with ovarian carcinoma and tested by flow
cytometry. Figure 2(a) shows the results of each individual
preparation as percentage of MR (CD206) and of CD14,
used as a pan-myeloid marker. MR expression was variable
and ranged from 17% to 72% (median value 39%). Such
heterogeneity is likely due to the fact that the MR is an
endocytic receptor that continuously shuttles from the cell
membrane to the early endosome compartments.
Immunohistochemistry of surgical samples of human
ovarian cancer was performed with two diﬀerent anti-CD206
mAb. Macrophages infiltrating the tumor stroma showed
strong reactivity (Figure 2(b)); these results confirmed that
the MR is expressed both by ascitic fluid macrophages and
by TAM infiltrating solid tumors.
To evaluate MR ability to internalize soluble particles,
we incubated TAM with FITC-Dextran, a known ligand
of MR. TAM rapidly internalized FITC-Dextran over 60′
period, with a kinetic similar to that of normal macrophages
diﬀerentiated in vitro with M-CSF (Figure 3(a)). Receptor
specificity was checked by pretreating cells with a blocking
anti-MR mAb, which resulted in significant inhibition of
internalization (Figure 3(b)). Pretreatment of TAM with
tumoral ascites (33% v/v) reduced by 50% FITC-Dextran
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Figure 2: Expression of the Mannose Receptor (MR) by human
TAM. (a) Flow cytometry analysis of purified preparations of
TAM from carcinoumatous ascites of patients with ovarian cancer.
TAMs were stained with anti-CD206 mAb (clone PAM-1) or
with anti-CD14. Twelve diﬀerent preparations were tested. (b)
Immunohistochemistry of 2 tumor samples from ovarian cancer
tissues stained with anti-CD206 mAbs (clone PAM-1, upper panels;
clone WE458, lower panels). Positive cells are brown stained
(magnification: left panels 40 x, right panels 100 x).
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Figure 3: TAMs express a functional endocytic MR. (a) Endocytosis
of FITC-Dextran by TAM (triangle) and by in vitro M-CSF-
diﬀerentiated macrophages (square), evaluated as Mean Fluores-
cence Intensity (MFI) by flow cytometry. Shown is a representative
experiment of 4 performed. (b) FITC-Dextran endocytosis in TAM
is significantly inhibited (P < .05 Student’s t tests) by pretreatment
with MR-ligands: unconjugated Dextran (1mg/mL), anti-CD206
mAb (10 ug/mL); and 33%v/v cell-free ascitic fluid from ovarian
tumors. Results are expressed as % relative to values of FITC-
Dextran uptake in control cells (medium) and are the mean +/−
SD of 3 experiments with 3 diﬀerent TAM preparations.
endocytosis, suggesting that ascitic fluids contained putative
ligand(s) of the MR. To have further proof of this, we
incubated TAMwith ascitic fluids prior to staining with anti-
CD206 mAb and analyzed in flow cytometry. Figure 4(a)
shows that tumoral ascites did induce the internalization
of the MR from the surface of TAM and of normal
macrophages: the percentage of surface MR decreased by 60–
80% while that of CD14 was unaﬀected (Figure 4(b)).
It is established that the MR can bind to MUC1
mucin and to the tumoral mucin TAG-72 [35, 36, 39, 40].
We therefore tested the mucin CA125 that is specifically
associated with ovarian cancer. Pretreatment of TAM with
TAG-72 or CA125 decreased MR expression, indicating that
also CA125 is able to engage the MR and to induce its
internalization (Figure 4(c)).
Notably, both unconjugated Dextran and the other MR
ligands tested did not completely block endocytosis or inhibit
receptor expression, most likely because—as mentioned
above—MR has high recycling ability. In support of this,
we noticed that in vitro culture of TAM for 24 hours in
the absence of ascitic fluid (i.e., out of the original micro-
environment), resulted in higher MR levels compared to
TAMs that were immediately tested after isolation (not
shown).
3.3. Mucin-Mediated Ligation of the MR Modulates Cytokine
Production in Human TAM. We previously reported in den-
dritic cells (DCs) that activation of the MR with an agonist
mAb or with MUC1 induced a regulatory/immunosuppres-
sive phenotype with a switch of cytokine production charac-
terized by low IL-12 and high IL-10 [27]. Hence, we tested
cytokine production of mucin-treated TAM. Figure 5(a)
shows that all tested MR ligands (TAG-72, CA125, and anti-
CD206) induced a significant increase of IL-10 in TAM as
well as in normal macrophages. By contrast, IL-12 secretion
was strongly decreased in normalmacrophages (Figure 5(a)).
TAMs, as already reported [41], are unable to produce
IL-12 even after optimal stimulation with LPS and IFNγ
(Figure 5(a)).
Macrophages and DC are a major source of chemokines
which importantly amplify the immunological network by
recruiting immunocompetent cells at tumor tissues. We
investigated the production of the chemokine CCL3, which
recruits Th1 and cytotoxic eﬀector lymphocytes. Figure 5(b)
shows that TAG-72 mucin strongly inhibited the secretion of
CCL3 by TAM and by in vitro generated macrophages and
mono-DC.
Overall these results demonstrate that the MR expressed
by TAM recognizes endogenous ligands present in the tumor
microenvironment, including the ovarian cancer specific
mucin CA125. Mucin-induced MR engagement modu-
lates the cytokine secretion of TAM toward an immune-
suppressive phenotype: increase of IL-10, absence of IL-
12 and decrease of CCL3. This cytokine profile is likely to
contribute to tumor immune escape.
4. Discussion
Very little is known about the expression and functional
role of CLRs in myeloid cells infiltrating tumors. This
study demonstrates that human TAMs express a number
of CLRs (e.g., Dectin-1, MDL-1, MGL, DCIR) and most
prominently the MR/CD206. Other receptors were not
significantly expressed (e.g., DC-SIGN, DEC205, Langerin),
in line with their preferential localization on dendritic and
Langerhans cells. ENDO180, which shares similarities with
the MR, was also poorly represented, and this finding is
consistent with its higher expression in fibroblasts [42]. We
focused our attention on the MR. Although it has long
been known that TAMs bear this receptor—and actually this
evidence served as paradigm of their M2-like polarization—
no functional characterization of MR-positive TAM has ever
been provided.
We found that both TAMs from solid tumors and
those from the ascitic fluid associated to advanced ovarian
cancer, have high membrane expression of the MR. Levels of
6 Clinical and Developmental Immunology
Medium
33% ascites
0
20
40
60
80
100
Po
si
ti
ve
ce
lls
(%
)
TAM 1 TAM 2 Macro 1 Macro 2
CD206
(a)
Medium
33% ascites
0
20
40
60
80
100
Po
si
ti
ve
ce
lls
(%
)
TAM 1 TAM 2 Macro 1 Macro 2
CD14
(b)
C
D
20
6
(M
FI
)
co
n
tr
ol
(%
)
Medium Dextran TAG72
200 IU/mL
CA125
20 IU/mL
CA125
200 IU/mL
P < .05
0
20
40
60
80
100
(c)
Figure 4: Tumoral mucins induce the internalization of the MR: flow cytometry expression of the MR /CD206 (a) and CD14 (b). Two
diﬀerent TAM preparations (TAM1 and TAM2) and 2M-CSF-diﬀerentiated normalmacrophages (Macro1 andMacro2) were pretreated (30
min. room temperature) with 33% v/v ascitic fluid from ovarian tumor patients, prior to staining with anti-CD206 or CD14 mAbs. Results
are shown as % of positive cells. (c) Purified TAMs were pretreated with unconjugated Dextran (1mg/mL); mucin Tag-72 (200 IU/mL);
mucin CA125 (20–200 IU/mL) prior to staining with anti-CD206 mAb. Results are shown as % relative to values of Mean fluorescence
Intensity (MFI) of CD206 in control cells (medium) and are the mean +/− SD of 4 experiments with 4 diﬀerent TAM preparations (3 TAM
preparations for CA125). P < .05 (Student’s t-tests).
expression were modulated by the tumormicroenvironment,
as components present in the ascitic fluid were able to induce
receptor internalization.
The MR is one of the oldest CLR described in macro-
phages [43, 44]. It is an endocytic and phagocytic receptor
that binds carbohydrate moieties on several pathogens such
as bacteria, fungi, parasites, and viruses and is therefore
considered a Pattern Recognition Receptor (PPR). However,
it has become increasingly clear that the MR is importantly
involved in the silent clearance of circulating inflammatory
molecules and degraded matrix components. Mice deficient
in the MR do not show increased susceptibility to infections
[45, 46] but have elevated levels of lysosomal hydrolases
and other glycoproteins which raise up during inflammation
and tissue remodelling [47, 48]. These in vivo experiments
highlighted its important role in the clearance of unwanted
molecules, especially for the MR localized at hepatic sinu-
soids.
Not only MR appears to be dispensable for pathogen
clearance but also it can negatively modulate pathogen-
elicited immune responses. We and others have pre-
viously reported that MR-ligation with ManLAM from
M. tubercolosis or with an agonist anti-MR antibody modu-
lates cytokine production in human DC, with a shift from
high to low IL-12, increased IL-10 levels, and defective
Th1 immune responses [26, 27]. These results have been
confirmed in this study in tumor macrophages activated
with agonist anti-MR mAbs. The mechanisms that account
for the regulatory functions of the MR are not completely
characterized. Unlike other CLRs, MR has no ITIM domain
[25]. It has been shown that some CLRs may interfere with
TLRs/NF-kB signalling [25, 49], and the MR can indeed
physically interact with TLR2 upon internalization [50]. In
addition, Pathak et al. reported that mannan induced the
upregulation of IRAK-M kinase, which was responsible for
the decreased production of proinflammatory cytokines by
inhibiting TLR-signaling [51, 52].
A number of recent studies corroborated the hypothesis
that the MR is implicated in the maintenance of homeostasis
and tolerance. Macrophages cocultured with mesenchymal
stem cells have high MR expression and produce IL-10 [53].
Royer et al. reported that allergens inducing Th2-polarized
responses express MR-binding carbohydrate moieties; the
receptor contributed to T cell polarization as its silencing in
Clinical and Developmental Immunology 7
0
1
2
P < .05
Macro TAM
IL
-1
2
Control
Anti-CD206
TAG-72
CA125
0
1
2
3
4
IL
-1
0
(n
g
)
P < .05
P < .05
Macro TAM
Control
Anti-CD206
TAG-72
CA125
/m
L
(n
g
)
/m
L
(a)
P < .05
P < .05
P < .05
DC Macro TAM
0
10
20
30
40
50
C
C
L
3
(n
g
)
/m
L
(b)
Figure 5: Modulation of cytokine production by tumoral mucin-engagement of the MR. (a) Purified TAM preparations or normal in vitro
diﬀerentiated macrophages were pretreated (10min. room temperature) with anti-CD206 (cloneWE458, 2 ug/mL), TAG-72 (200UI/mL), or
CA125 (200UI/mL) prior to stimulation with LPS (1 ug/mL, 24 hrs). Levels of IL-10 (upper panels) and IL-12 (lower panels) were measured
in supernatants by ELISA. Results are mean +/− SE of 6 diﬀerent TAM preparations for IL-10 and 3 for IL-12 (P < .05, Student’s t-tests).
(b) Purified TAM, normal in vitro diﬀerentiated macrophages, and mono-DC were pretreated (10 min. room temperature) with TAG-72
(200UI/mL) prior to stimulation with LPS (1 ug/mL, 24 hrs). Levels of CCL3 were measured in supernatants by ELISA. Results are mean
+/− SE of 4 diﬀerent TAM preparations, 3 for macrophages, and mono-DC. P < .05 (Student’s t-tests).
DC strongly impaired Th2 development [54]. Macrophages
localized at sites where inflammation could be particularly
harmful are usually strongly MR-positive (e.g., alveolar
macrophages and brain microglia). Further, at the maternal-
foetal interface the presence of immune cells is important to
preserve tolerance as well as for active remodelling of uterine
vessels. Decidual macrophages are a major source of IL-10
and IDO [55] and express high levels of the MR [40]. MR
recognizes several endogenous ligands and acts as a bridge
between innate immunity and homeostasis [25, 56]. For
instance, circulating hormones, like lutropin and thyrotropin
are bound by the MR cystein-rich domain [57]. Collagen is
another MR-ligand and the receptor may serve important
scavenger functions [58].
In the context of a tumor microenvironment, where
highly glycosylated molecules such as mucins are present
[59] CLRs encounter several putative ligands. MGL and DC-
SIGN recognize cancer-specific glycosylation changes of the
mucin MUC1, in particular the carbohydrate sialyl LewisX
and the sialyl TN epitope [60]; MUC1 and TAG-72 bind also
the MR [27, 35, 36]. We previously reported that mono-
DCs diﬀerentiated in the presence of tumor cell-derived
mucins have a tolerogenic/regulatory cytokine profile [34].
In the present study we extended this observation to tumor
macrophages: TAMs bound and internalized both TAG-72
and the ovarian cancer-associated mucin CA125 via the MR,
indicating a specific recognition by this receptor. Further,
these mucins interfered with the LPS-induced production
of IL-10 and of the chemokine CCL3. These results are
in line with the observation that another tumoral mucin,
the carcinoembryonic antigen (CEA) highly expressed by
colon cancer cells, binds DC-SIGN on DC and induces
increased secretion of IL-10 and IL-6 [61]. Hence, evidence
is accumulating that CLR recognition of tumor glycans
leads to the expression of the potent immunoregulatory
cytokine IL-10. In the tumor microenvironment IL-10 has
detrimental eﬀects on immune responses as it promotes the
polarization of M2 macrophages inhibits the diﬀerentiation
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of Th1 lymphocytes while favouring that of Treg [62].
Interestingly, a recent study showed that distinct TAM
subsets can be distinguished on the basis of diﬀerential
expression of MHC II molecules. TAMs characterized by
MHC IIlow and suppressive activity on T cell proliferation
have higher expression of the MR [63].
In addition, MR is expressed by endothelial cells of
lymphatic vessels [64] and it has been demonstrated to be
implicated in the dissemination of tumor cells along lym-
phatics [33]. Recently, Arteta et al. reported that MR-positive
liver sinusoidal vessels also support hepatic metastasis of
colon cancer cells by a mechanism that involves IL-1-induced
upregulation of the MR [65].
Thus, while under physiological conditions the regula-
tory eﬀect of CLRs on innate immunity cells is finalized to
the preservation of homeostasis, in pathological conditions
such as cancer, CLR activity may hamper the activation of
a protective immune response and actually favour tumor
spread.
In conclusion, we have demonstrated that the MR on
human TAM can be engaged by mucins present in the tumor
microenvironment. This interaction further enhances their
immunosuppressive phenotype and can be considered as
another mechanism of tumor immune evasion.
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